Ian W Flinn Selected Research

Proteins (Proteins, Gene)

1/2022	A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
1/2021	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
2/2014	A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.
4/2003	Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ian W Flinn Research Topics

Disease

57	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2023 - 02/2002
39	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2024 - 02/2002
29	Neoplasms (Cancer) 01/2024 - 02/2002
22	Lymphoma (Lymphomas) 11/2023 - 09/2002
20	Neutropenia 10/2023 - 09/2011
18	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2022 - 02/2004
13	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/2022 - 02/2010
12	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2023 - 01/2005
11	Infections 07/2023 - 08/2003
10	Disease Progression 10/2023 - 08/2004
10	Diarrhea 05/2022 - 03/2014
9	B-Cell Lymphoma (Lymphoma, B Cell) 11/2023 - 04/2007
9	Pneumonia (Pneumonitis) 04/2021 - 03/2014
7	Fatigue 01/2023 - 04/2007
7	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 06/2013
7	Thrombocytopenia (Thrombopenia) 01/2021 - 03/2007
6	Febrile Neutropenia 05/2022 - 12/2014
6	Leukemia 01/2019 - 02/2002
4	Residual Neoplasm 01/2023 - 01/2019
4	Nausea 12/2018 - 05/2014
4	Exanthema (Rash) 11/2018 - 09/2011
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2021 - 06/2013
3	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 08/2004
3	Multiple Myeloma 01/2021 - 01/2011
3	Colitis 01/2019 - 12/2016
3	Fever (Fevers) 12/2018 - 04/2007
3	Anemia 12/2018 - 05/2014
2	Hemorrhage 07/2023 - 01/2017
2	Lymphocytosis 07/2023 - 03/2013
2	Atrial Fibrillation 07/2023 - 04/2021
2	Hypertension (High Blood Pressure) 07/2023 - 01/2022
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023 - 06/2021
2	Sepsis (Septicemia) 04/2021 - 03/2017
2	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 04/2021 - 03/2017
2	Body Weight (Weight, Body) 01/2020 - 12/2017
2	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 10/2019 - 08/2003
2	Tumor Lysis Syndrome 01/2019 - 12/2014
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 10/2017
2	Vomiting 04/2016 - 05/2014
2	Lymphadenopathy 05/2014 - 03/2013
2	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2007 - 04/2006
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2023

Drug/Important Bio-Agent (IBA)

44	Rituximab (Mabthera)FDA Link 10/2023 - 02/2002
19	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2021 - 08/2003
18	ibrutinibIBA 01/2024 - 07/2013
15	Bendamustine Hydrochloride FDA Link 01/2022 - 05/2014
12	fludarabineIBA 11/2018 - 02/2002
11	idelalisibIBA 01/2021 - 03/2013
10	Monoclonal AntibodiesIBA 10/2023 - 02/2002
10	Prednisone (Sone)FDA LinkGeneric 01/2021 - 08/2003
10	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 08/2003
9	Agammaglobulinaemia Tyrosine KinaseIBA 07/2023 - 05/2015
9	obinutuzumabIBA 01/2022 - 01/2019
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 08/2003
8	Chlorambucil (Leukeran)FDA Link 01/2022 - 05/2006
7	ofatumumab FDA Link 01/2019 - 01/2016
6	Transaminases (Aminotransferases)IBA 12/2021 - 03/2014
6	ibritumomab tiuxetan (Zevalin)FDA Link 06/2021 - 02/2002
5	Chimeric Antigen ReceptorsIBA 11/2023 - 12/2017
5	axicabtagene ciloleucelIBA 11/2023 - 12/2017
5	venetoclaxIBA 07/2023 - 01/2019
5	YttriumIBA 06/2021 - 02/2002
5	duvelisibIBA 12/2019 - 01/2018
4	acalabrutinibIBA 01/2024 - 01/2020
4	zanubrutinibIBA 01/2024 - 10/2020
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2003
3	AntibodiesIBA 10/2023 - 08/2003
3	Lenalidomide (CC 5013)FDA Link 10/2022 - 01/2018
3	Phosphatidylinositols (Phosphatidylinositol)IBA 12/2021 - 05/2014
3	umbralisibIBA 12/2021 - 01/2018
3	nilotinib FDA Link 07/2021 - 09/2011
3	Imatinib Mesylate (Gleevec)FDA Link 07/2021 - 09/2011
3	Bortezomib (Velcade)FDA Link 01/2018 - 09/2006
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2018 - 05/2014
3	Interleukin-2 (IL2)IBA 10/2007 - 12/2005
2	pirtobrutinibIBA 07/2023 - 01/2021
2	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 04/2004
2	brexucabtagene autoleucelIBA 01/2023 - 01/2020
2	3- (5- amino- 2- methyl- 4- oxoquinazolin- 3(4H)- yl)piperidine- 2,6- dioneIBA 05/2022 - 02/2022
2	carfilzomibIBA 01/2021 - 05/2015
2	PanobinostatIBA 01/2021 - 05/2015
2	Phosphotransferases (Kinase)IBA 01/2021 - 05/2014
2	enasidenibIBA 01/2019 - 10/2017
2	R-CHOP protocolIBA 01/2019 - 02/2010
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2018 - 05/2014
2	Alanine Transaminase (SGPT)IBA 01/2018 - 05/2014
2	Alkylating AgentsIBA 01/2017 - 03/2014
2	TRU 016IBA 01/2015 - 02/2014
2	Immunoglobulins (Immunoglobulin)IBA 06/2014 - 02/2004
2	lumiliximabIBA 01/2010 - 08/2007
2	Alemtuzumab (Campath)FDA Link 01/2005 - 05/2004
2	Complement System Proteins (Complement)IBA 04/2003 - 02/2002
1	Bispecific AntibodiesIBA 03/2024

Therapy/Procedure

42	Therapeutics 11/2023 - 03/2002
17	Drug Therapy (Chemotherapy) 10/2022 - 02/2002
6	Radioimmunotherapy 06/2021 - 02/2002
4	Stem Cell Transplantation 01/2022 - 03/2002
4	Transplantation 10/2007 - 01/2005
2	Duration of Therapy 07/2023 - 01/2023
2	Immunotherapy 01/2018 - 06/2014